Hepatology Communications,
Journal Year:
2023,
Volume and Issue:
7(10)
Published: Sept. 27, 2023
NAFLD
is
the
most
common
chronic
liver
disease
worldwide,
characterized
by
lipid
accumulation
in
liver,
and
usually
evolves
from
steatohepatitis
to
fibrosis,
cirrhosis,
or
even
HCC.
Its
incidence
rapidly
rising
parallel
with
increasing
prevalence
of
obesity
metabolic
syndrome.
Current
therapies
are
limited
lifestyle
changes
including
dietary
intervention
exercise,
which
modification
exerts
an
important
part
losing
weight
preventing
NAFLD.
In
this
review,
we
briefly
discuss
roles
mechanisms
components
fructose,
non-nutritive
sweeteners,
fat,
proteins,
vitamins
progression
prevention
We
also
summarize
several
popular
patterns
such
as
calorie-restricted
diets,
intermittent
fasting,
ketogenic
Mediterranean
approach
stop
hypertension
diets
compare
effects
low-fat
low-carbohydrate
development
Moreover,
potential
drugs
targeting
metabolic-related
targets
Current Issues in Molecular Biology,
Journal Year:
2023,
Volume and Issue:
45(11), P. 9132 - 9148
Published: Nov. 15, 2023
Metabolic-associated
liver
disease
(MAFLD)
affects
up
to
70%
of
overweight
and
more
than
90%
morbidly
obese
people,
its
pathogenesis
is
rather
complex
multifactorial.
The
criteria
for
MAFLD
include
the
presence
hepatic
steatosis
in
addition
one
following
three
criteria:
or
obesity,
type
2
diabetes
mellitus
(T2DM),
evidence
metabolic
dysregulation.
If
specific
are
present,
diagnosis
can
be
made
regardless
alcohol
consumption
previous
disease.
pathophysiological
mechanisms
MAFLD,
including
inflammation,
lipotoxicity,
mitochondrial
disfunction,
oxidative
stress,
as
well
impact
intestinal
gut
microbiota,
constantly
being
elucidated.
Treatment
strategies
that
continually
emerging
based
on
different
key
points
pathogenesis.
Yet,
ideal
therapeutic
option
has
still
not
been
found
future
research
great
importance,
represents
a
multisystemic
with
numerous
complications.
Journal of Clinical and Translational Hepatology,
Journal Year:
2024,
Volume and Issue:
000(000), P. 000 - 000
Published: July 31, 2024
Given
the
global
prevalence
and
rising
incidence
of
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
absence
licensed
medications
is
striking.
A
deeper
understanding
heterogeneous
nature
MASLD
has
recently
contributed
to
discovery
novel
groups
agents
potential
repurposing
currently
available
medications.
therapies
center
on
four
major
pathways.
Considering
close
relationship
between
type
2
diabetes,
first
approach
involves
antidiabetic
medications,
including
incretins,
thiazolidinedione
insulin
sensitizers,
sodium-glucose
cotransporter
inhibitors.
The
second
targets
hepatic
lipid
accumulation
resultant
stress.
Agents
in
this
group
include
peroxisome
proliferator-activated
receptor
agonists
(e.g.,
pioglitazone,
elafibranor,
saroglitazar),
bile
acid-farnesoid
X
axis
regulators
(obeticholic
acid),
de
novo
lipogenesis
inhibitors
(aramchol,
NDI-010976),
fibroblast
growth
factor
21/19
analogs.
third
focuses
targeting
oxidative
stress,
inflammation,
fibrosis.
antioxidants
(vitamin
E),
tumor
necrosis
α
pathway
(emricasan,
pentoxifylline,
ZSP1601),
immune
modulators
(cenicriviroc,
belapectin).
final
gut
(IMM-124e,
solithromycin).
Combination
different
pathogenetic
pathways
may
provide
an
alternative
treatment
with
higher
efficacy
fewer
side
effects.
This
review
aimed
update
these
